Apo-Ident Revenue and Competitors

Dresden,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Apo-Ident's estimated annual revenue is currently $3.4M per year.(i)
  • Apo-Ident's estimated revenue per employee is $155,000

Employee Data

  • Apo-Ident has 22 Employees.(i)
  • Apo-Ident grew their employee count by 0% last year.

Apo-Ident's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Apo-Ident?

HiperScan GmbH branched off from the Fraunhofer Institute for Photonic Microsystems, Dresden, in 2006 and is a successful, medium-sized technology company. With the help of scanning grating technology developed at the Fraunhofer Institute, the high-performance SGS1900 spectrometer was developed as part of further research collaborations. This established the basis for the very successful and cost-effective NIR-analysis system Apo-Ident, which is distributed in Germany and internationally. It is a near infrared spectrometer that has been specially designed for identifying raw materials in pharmacies. With this system, HiperScan is the market leader for raw material identification in German pharmacies. As one of the fastest growing technology companies, HiperScan GmbH was presented the Technology Fast 50 Award in 2015.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Apo-Ident News

2022-02-22 - Apo-Ident auf der expopharm 2018 - Erstmalig Ausstellung Labor ...

Der NIR-Marktführer stellt das Analysesystem Apo-Ident aus und präsentiert erstmalig sein Labor- und Rezepturbedarf Sortiment für Apotheken.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.2M22N/AN/A
#2
$3.4M2310%N/A
#3
$5.5M24-27%N/A
#4
$2.4M244%N/A
#5
$4.6M249%N/A